Consensus Clene Inc.

Stocks

CLNN

US1856342019

Biotechnology & Medical Research

Market Closed - Nasdaq 01:30:00 01/10/2026 am IST			5-day change	1st Jan Change
4.080 ^USD	-0.49%		-4.90%	-30.49%

16/09	Top Midday Gainers	MT
14/08	Clene Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Clene Inc.

Evolution of the Target Price: Clene Inc.

Changes in Analyst Recommendations: Clene Inc.

8968c24ca08.qiCeut1CFYpoztcNsXd4nTYRK_7fHd0vsjf48YELTsE.wVf_yqh6VuINlK1S0jgZ6ANAfpqeW6xK32SbmuZgPZv8Q8HvlTN8vxqfhg~6029f377da2d41399b9e6d0d773a25bc

Analysts' recommendations: Clene Inc.

10/24/10	EF Hutton Initiates Clene at Buy With $23 Price Target	MT
30/23/30	Benchmark Cuts Price Target on Clene to $5 From $7, Maintains Buy Rating	MT
21/23/21	HC Wainwright Cuts Price Target on Clene to $7 From $15, Keeps Buy Rating	MT
20/23/20	EF Hutton Adjusts Clene Price Target to $10 From $13, Maintains Buy Rating	MT
16/23/16	Cantor Fitzgerald Adjusts Price Target on Clene to $4 From $5, Maintains Overweight Rating	MT
10/23/10	Benchmark Adjusts Price Target on Clene to $7 From $11, Keeps Buy Rating	MT
10/23/10	Cantor Fitzgerald Adjusts Price Target on Clene to $8 From $6, Maintains Buy Rating	MT
08/23/08	EF Hutton Starts Clene at Buy With $13 Price Target	MT
04/22/04	Oppenheimer Downgrades Clene to Perform From Outperform, Removes $17 Price Target	MT
04/22/04	Benchmark Adjusts Clene's Price Target to $11 From $25, Reiterates Buy Rating	MT
04/22/04	Canaccord Genuity Adjusts Clene's Price Target to $6 From $10, Reiterates Buy Rating	MT
17/22/17	Oppenheimer Adjusts Clene's Price Target to $17 From $16, Maintains Outperform Rating	MT
16/22/16	Cantor Fitzgerald Adjusts Clene Price Target to $12 From $10, Maintains Overweight Rating	MT
18/22/18	HC Wainwright Initiates Clene at Buy With $16 Price Target	MT
02/22/02	Canaccord Genuity Starts Clene at Buy With $10 Price Target	MT
15/22/15	Oppenheimer Adjusts Clene's Price Target to $19 From $20, Maintains Outperform Rating	MT
03/21/03	Cantor Fitzgerald Adjusts Clene's Price Target to $15 From $24, Reiterates Overweight Rating	MT
28/21/28	Clene : Oppenheimer Initiates Coverage on Clene With Outperform Rating, $20 Price Target	MT
20/21/20	Clene : Maxim Group Starts Clene at Buy With $18 Price Target	MT
03/21/03	Clene : Cantor Fitzgerald Starts Clene at Overweight With $22 Price Target	MT
02/21/02	Clene : Benchmark Starts Clene at Buy With $25 Price Target	MT
03/21/03	Clene : Roth Capital Starts Clene at Buy with $24 Price Target	MT

More recommendations

Bio Therapeutic Drugs

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CLENE INC.					+689.22%
	WUXI APPTEC CO., LTD.					+11.79%
	ARGENX SE					+21.92%
	LONZA GROUP AG					+19.64%
	IQVIA HOLDINGS INC.					+7.4%
	REVOLUTION MEDICINES, INC.					+25.43%
	BEONE MEDICINES AG					+18.27%
	CELLTRION, INC.					+50.7%
	WUXI BIOLOGICS (CAYMAN) INC.					+3.91%
	INSMED INCORPORATED					+73.24%
	Average					+92.15%
	Weighted average by Cap.					+22.29%